Vol. 8, Issue No. 1: JANUARY 2009 – EXECUTIVE SUMMARY Is There Life After Pharma? Upfront Commentary
Pfizer has announced plans to eliminate up to 18,000 jobs in 2009. Even pharmaceutical companies that are not growing by acquisition, but shrinking by design (eg, GSK), are cutting back on personnel.
Before the year is out you probably will know one or two or more people who are no longer employed in this industry. These people may have several employment options, but they may no longer be sought after by any company related to the drug industry. So, what is life like after pharma?
Read this entire OpEd piece by John Mack here:
www.news.pharma-mkting.com/Article-Upfront-PMN82-Feb09.pdf The Future of DTC Advertising Is a Perfect Storm Brewing?
Experts don’t know if it’s the economy, lack of new drugs in pharma’s pipeline, or the new pro-regulation political climate, but 2009 is shaping up to be the year that direct-to-consumer (DTC) advertising will suffer a round of budget cuts and setbacks not seen in a long time.
How can we predict the future of DTC given all these influences? As usual, Pharma Marketing News hosted an online survey to tap into the knowledge and views of readers to help answer that question and get some insights from experts. The survey ran from November 12, 2008 through January 19, 2009.
The results, including comments from survey respondents and DTC experts, are summarized in this article.
Topic headings include:
- Even Pharma CEOs Question DTC’s Future
- Wolfe in the Henhouse
- Decline in DTC Ad Spending Likely
- Let’s Focus on Effectiveness, Not Dollars Spent as a Measure of DTC Success
- Questionable ROI
- Should DTC Be Banned?
- What About a DTC Moratorium?
- Business Tax Deduction
- Communicating Risk
Read this article now. It’s FREE…
The ePharma Pioneer Club™ Convincing Pharma Marketers to Engage in “e”
Pharma Marketing Network’s ePharma Pioneer Club™ is an EXCLUSIVE, members-only Facebook Group through which pharmaceutical eMarketing experts “meet” to discuss and exchange views on how to advance the use of the Internet and other technologies in pharmaceutical marketing, sales, and communications.
ePharma Pioneers believe fervently that they could make pharma health communications more effective, relevant, and useful if they had the proper level of resources and support from management.
If you believe you are a pioneer in the use of technology in marketing and like the idea of a small, exclusive club of like-minded people who are tired of swimming against the current when it comes to pharma eMarketing and eCommunications, then the ePharma Pioneer Club may just be right for you.
This article introduces the Club and its mission.
Topic headings include:
- Engage, Educate, and Entertain
- Why a Club?
- Criteria for Membership
- Knowledge of Pharma Marketing A Must
- Club Member Jonathan Richman Takes on the Myth of Adverse Event Reporting
- Current Club Members
- Want to Join the Club?
Read this article now. It’s FREE…
FDA Finalizes Guidance on Distribution of Reprints Clarifies How Manufacturers Can Hand Out Journal Articles to Docs
The FDA recently finalized its “Good Reprint Practices for the Distribution of Medical Journal Articles and Medical or Scientific Reference Publications on Unapproved New Uses of Approved Drugs and Approved or Cleared Medical Devices U.S.”
“There is a more defined line which manufacturers and companies can look at and figure out, ‘how can I make this work for me and how can I make this work for my company,”’ says Erin Reilly Lewis, Esq., counsel with Baker and Daniels in Indianapolis.
This guest article written by Michelle Leppert, Managing Editor, HCPro, Inc., outlines the major provisions of FDA’s reprint guidelines.
Topic headings include:
- Requirements in the guidance
- Appropriate information
- Off-label promotion still prohibited
- Financial disclosures
- Industry need for guidance
Read this article now. It’s FREE…
he Hypocrisy of Healthcare Marketing Restrictions Stand Up for Healthcare Marketing Free Speech
Ayn Rand, author of Atlas Shrugged, believed that any restriction of or interference in free enterprise (eg, regulations) causes more problems than it solves. Yet many people believe the lack of government regulation or enforcement of regulations is the cause of the current economic debacle.
Pharmaceutical marketing, some say, has benefited by the recent “dramatic drop off of enforcement of domestic laws.” Under a Democratic administration, they say, there will be a new emphasis on enforcement of current regulations as well as new regulations.
The drug industry’s response has been to increase self-regulation, but Dmitriy Kruglyak of Trusted.MD Network thinks this is cave in to hypocritical attacks by the media and other critics of the industry.
“Well-intentioned measures can go very wrong,” says Kruglyak. “Time to call out the disturbing hypocrisy directed at healthcare marketers” was his rallying cry in a recent post he made entitled “New Year Resolution: Stand Up to Healthcare Marketing Hypocrisy!”
This article summarizes Kruglyak’s thesis and offers a counterpoint from John Mack, the editor of Pharma Marketing News. Hopefully, it will generate further discussion from readers.
Topic headings include:
- Myths promulgated by the media
- Zeal to Regulate
- Group drops event, says doc-gift rules too strict
- Unpaid, Unbiased?
- Lack of Transparency
- Democracy in Advertising
Read this article now. It’s FREE…
